Myeloproliferative Disease | A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases.
Myeloproliferative Disease research study
What is the primary objective of this study?
Pulmonary hypertension (PH) is defined as a group of diseases characterised by an elevated mean pulmonary artery pressure (Ppa) ≥25 mmHg at rest. Recently, chronic myeloproliferative diseases (CMPD) associated with pulmonary hypertension were included in the group 5 category, corresponding to PH for which the aetiology is unclear and/or multifactorial. CMPD include chronic myelogenous leukaemia, chronic neutrophilic leukaemia and chronic eosinophilic leukaemia (which primarily express a myeloid phenotype and polycythaemia vera), idiopathic myelofibrosis, and essential thrombocytosis in which erythroid or megakaryocytic hyperplasia predominates. The purpose of this research: 1. Assess Prevalence of PH in patients with CMPD in Northern Israel 2. Describe the demographics and clinical course in patients with CMPD who are diagnosed with PH.
Who is eligible to participate?
Inclusion Criteria: 1) consenting patients diagnosed with a myeloproliferative disease Exclusion Criteria: 1) Refusal to have an echocardiogram or answer the St. George respiratory questionnaire
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Other:myeloproliferative diseaseEchocardiogram, demographic data, St George respiratory questioner
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
myeloproliferative diseasePatients with Myeloproliferative Diseases as specified under inclusion and exclusion criteria
Start Date: July 2013
Primary Outcome: pulmonary hypertension
Secondary Outcome: St George Respiratory Questionnaire
Study sponsors, principal investigator, and references
Principal Investigator: Shoshan Perek, MD
Lead Sponsor: Carmel Medical Center